The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Role of favipiravir in the treatment of COVID-19
Open accessAbstract
The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the researchers to strive to develop drugs or vaccines to prevent or halt the progression of this ailment. To hasten the treatment process, repurposed drugs are being evaluated. Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2. It has a wide therapeutic safety margin indicated by a wide CC50/EC50 ratio for a high dose. From the clinical studies in COVID-19, it has shown rapid viral clearance as compared to lopinavir/ritonavir (LPV/RTV) and superior recovery rate than umifenovir. Overall, favipiravir has shown promising results in clinical studies in China, Russia, and Japan, and more trials are underway in multiple countries, including USA, UK, and India. Recently, treatment guidelines from many countries and some states from India have included favipiravir in the treatment protocol. This review provides insights into the evidence-based evolving role of favipiravir in the management of COVID-19 infection with emphasis on benefits of initiating an early antiviral therapy with special focus on favipiravir, its pharmacodynamic, pharmacokinetic, in vitro, clinical data, and inclusion in the treatment protocols of COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., et al. (2020) · Engineering · doi:10.1016/j.eng.2020.03.007 · Cited by 1,357
RetractedWang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
The National Center for Biotechnology Information
Benson, D., Boguski, M., Lipman, D. J., & Ostell, J. (1990) · Genomics · doi:10.1016/0888-7543(90)90583-g · Cited by 5,126
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Li, G., & De Clercq, E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00016-0 · Cited by 1,729
Berlin, D. A., Gulick, R. M., & Martinez, F. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp2009575 · Cited by 1,439
Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak
Zhang, T., Wu, Q., & Zhang, Z. (2020) · Current Biology · doi:10.1016/j.cub.2020.03.022 · Cited by 1,397
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,390
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Another Decade, Another Coronavirus
Perlman, S. (2020) · New England Journal of Medicine · doi:10.1056/nejme2001126 · Cited by 1,062
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.683296 · Cited by 849
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Shiraki, K., & Daikoku, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107512 · Cited by 573
Sissoko, D., Laouenan, C., Folkesson, E., M’Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., Danel, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001967 · Cited by 478
Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak
Zhang, T., Wu, Q., & Zhang, Z. (2020) · Current Biology · doi:10.1016/j.cub.2020.03.063 · Cited by 426
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
Du, Y., & Chen, X. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1844 · Cited by 418
Magleby, R., Westblade, L. F., Trzebucki, A., Simon, M. S., Rajan, M., Park, J., Goyal, P., Safford, M. M., & Satlin, M. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa851 · Cited by 412
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Delang, L., Abdelnabi, R., & Neyts, J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.03.003 · Cited by 388
Wu, J., Li, W., Shi, X., Chen, Z., Jiang, B., Liu, J., Wang, D., Liu, C., Meng, Y., Cui, L., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13063 · Cited by 335
The mechanism of resistance to favipiravir in influenza
Goldhill, D. H., te Velthuis, A. J. W., Fletcher, R. A., Langat, P., Zambon, M., Lackenby, A., & Barclay, W. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811345115 · Cited by 298
Shannon, A., Selisko, B., Le, N.-T.-T., Huchting, J., Touret, F., Piorkowski, G., Fattorini, V., Ferron, F., Decroly, E., Meier, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18463-z · Cited by 296
A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
Pilkington, V., Pepperrell, T., & Hill, A. (2020) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30016-9 · Cited by 271
Jin, Z., Smith, L. K., Rajwanshi, V. K., Kim, B., & Deval, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068347 · Cited by 268
Influenza virus polymerase inhibitors in clinical development
Hayden, F. G., & Shindo, N. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000532 · Cited by 254
Use of antiviral drugs to reduce COVID-19 transmission
Mitjà, O., & Clotet, B. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30114-5 · Cited by 230
Human Liver Aldehyde Oxidase: Inhibition by 239 Drugs
Obach, R. S., Huynh, P., Allen, M. C., & Beedham, C. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003260336 · Cited by 224
Doi, Y., Hibino, M., Hase, R., Yamamoto, M., Kasamatsu, Y., Hirose, M., Mutoh, Y., Homma, Y., Terada, M., Ogawa, T., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01897-20 · Cited by 223
Goyal, A., Cardozo-Ojeda, E. F., & Schiffer, J. T. (2020) · Science Advances · doi:10.1126/sciadv.abc7112 · Cited by 189
Arshad, U., Pertinez, H. E., Box, H., Tatham, L. M., Rajoli, R. K. R., Curley, P., Neary, M., Sharp, J., Liptrott, N. J., Valentijn, A., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1909 · Cited by 161
Wang, Y., Fan, G., Salam, A., Horby, P., Hayden, F. G., Chen, C., Pan, J., Zheng, J., Lu, B., Guo, L., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz656 · Cited by 158
Bai, C., Mu, J., Kargbo, D., Song, Y., Niu, W., Nie, W., Kanu, A., Liu, W., Wang, Y., Dafae, F. M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw571 · Cited by 153
Favipiravir: A New Medication for the Ebola Virus Disease Pandemic
Nagata, T., Lefor, A. K., Hasegawa, M., et al. (2014) · Disaster Medicine and Public Health Preparedness · doi:10.1017/dmp.2014.151 · Cited by 141
Weiss, A., Jellingsø, M., & Sommer, M. O. A. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102916 · Cited by 139
Caroline, A. L., Powell, D. S., Bethel, L. M., Oury, T. D., Reed, D. S., & Hartman, A. L. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002790 · Cited by 110
Rattanaumpawan, P., Jirajariyavej, S., Lerdlamyong, K., Palavutitotai, N., & Saiyarin, J. (2022) · Antibiotics · doi:10.3390/antibiotics11060805 · Cited by 64
The Rationale for Potential Pharmacotherapy of COVID-19
Saber-Ayad, M. M., Saleh, M. A., & Abu‐Gharbieh, E. (2020) · Pharmaceuticals · doi:10.3390/ph13050096 · Cited by 61
A prospect on the use of antiviral drugs to control local outbreaks of COVID-19
Torneri, A., Libin, P., Vanderlocht, J., Vandamme, A., Neyts, J. H., & Hens, N. (2020) · BMC Medicine · doi:10.1186/s12916-020-01636-4 · Cited by 52
Metadata
- Authors
- Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 102
- Pages
- 501-508
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W3095251247
- Cited by
- 462
- References
- 38
- FWCI
- 10.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.